Thomas E Merchant1, Jane E Schreiber2, Shengjie Wu3, Renin Lukose4, Xiaoping Xiong3, Amar Gajjar5. 1. Division of Radiation Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee. Electronic address: thomas.merchant@stjude.org. 2. Department of Psychology, St. Jude Children's Research Hospital, Memphis, Tennessee. 3. Department of Biostatistcs, St. Jude Children's Research Hospital, Memphis, Tennessee. 4. Division of Radiation Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee. 5. Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Abstract
PURPOSE: To prospectively follow children treated with craniospinal irradiation to determine critical combinations of radiation dose and volume that would predict for cognitive effects. METHODS AND MATERIALS: Between 1996 and 2003, 58 patients (median age 8.14 years, range 3.99-20.11 years) with medulloblastoma received risk-adapted craniospinal irradiation followed by dose-intense chemotherapy and were followed longitudinally with multiple cognitive evaluations (through 5 years after treatment) that included intelligence quotient (estimated intelligence quotient, full-scale, verbal, and performance) and academic achievement (math, reading, spelling) tests. Craniospinal irradiation consisted of 23.4 Gy for average-risk patients (nonmetastatic) and 36-39.6 Gy for high-risk patients (metastatic or residual disease >1.5 cm(2)). The primary site was treated using conformal or intensity modulated radiation therapy using a 2-cm clinical target volume margin. The effect of clinical variables and radiation dose to different brain volumes were modeled to estimate cognitive scores after treatment. RESULTS: A decline with time for all test scores was observed for the entire cohort. Sex, race, and cerebrospinal fluid shunt status had a significant impact on baseline scores. Age and mean radiation dose to specific brain volumes, including the temporal lobes and hippocampi, had a significant impact on longitudinal scores. Dichotomized dose distributions at 25 Gy, 35 Gy, 45 Gy, and 55 Gy were modeled to show the impact of the high-dose volume on longitudinal test scores. The 50% risk of a below-normal cognitive test score was calculated according to mean dose and dose intervals between 25 Gy and 55 Gy at 10-Gy increments according to brain volume and age. CONCLUSIONS: The ability to predict cognitive outcomes in children with medulloblastoma using dose-effects models for different brain subvolumes will improve treatment planning, guide intervention, and help estimate the value of newer methods of irradiation.
PURPOSE: To prospectively follow children treated with craniospinal irradiation to determine critical combinations of radiation dose and volume that would predict for cognitive effects. METHODS AND MATERIALS: Between 1996 and 2003, 58 patients (median age 8.14 years, range 3.99-20.11 years) with medulloblastoma received risk-adapted craniospinal irradiation followed by dose-intense chemotherapy and were followed longitudinally with multiple cognitive evaluations (through 5 years after treatment) that included intelligence quotient (estimated intelligence quotient, full-scale, verbal, and performance) and academic achievement (math, reading, spelling) tests. Craniospinal irradiation consisted of 23.4 Gy for average-risk patients (nonmetastatic) and 36-39.6 Gy for high-risk patients (metastatic or residual disease >1.5 cm(2)). The primary site was treated using conformal or intensity modulated radiation therapy using a 2-cm clinical target volume margin. The effect of clinical variables and radiation dose to different brain volumes were modeled to estimate cognitive scores after treatment. RESULTS: A decline with time for all test scores was observed for the entire cohort. Sex, race, and cerebrospinal fluid shunt status had a significant impact on baseline scores. Age and mean radiation dose to specific brain volumes, including the temporal lobes and hippocampi, had a significant impact on longitudinal scores. Dichotomized dose distributions at 25 Gy, 35 Gy, 45 Gy, and 55 Gy were modeled to show the impact of the high-dose volume on longitudinal test scores. The 50% risk of a below-normal cognitive test score was calculated according to mean dose and dose intervals between 25 Gy and 55 Gy at 10-Gy increments according to brain volume and age. CONCLUSIONS: The ability to predict cognitive outcomes in children with medulloblastoma using dose-effects models for different brain subvolumes will improve treatment planning, guide intervention, and help estimate the value of newer methods of irradiation.
Authors: A W Walter; R K Mulhern; A Gajjar; R L Heideman; D Reardon; R A Sanford; X Xiong; L E Kun Journal: J Clin Oncol Date: 1999-12 Impact factor: 44.544
Authors: Kim Edelstein; Brenda J Spiegler; Sharon Fung; Tony Panzarella; Donald J Mabbott; Natalie Jewitt; Norma Mammone D'Agostino; Warren P Mason; Eric Bouffet; Uri Tabori; Normand Laperriere; David C Hodgson Journal: Neuro Oncol Date: 2011-03-02 Impact factor: 12.300
Authors: R J Packer; J Goldwein; H S Nicholson; L G Vezina; J C Allen; M D Ris; K Muraszko; L B Rorke; W M Wara; B H Cohen; J M Boyett Journal: J Clin Oncol Date: 1999-07 Impact factor: 44.544
Authors: Ingrid Tonning Olsson; Tara M Brinkman; Mingjuan Wang; Matthew J Ehrhardt; Pia Banerjee; Daniel A Mulrooney; I-Chan Huang; Kirsten K Ness; Michael W Bishop; Deokumar Srivastava; Leslie L Robison; Melissa M Hudson; Kevin R Krull Journal: Cancer Date: 2020-01-08 Impact factor: 6.860
Authors: Kevin R Krull; Kristina K Hardy; Lisa S Kahalley; Ilse Schuitema; Shelli R Kesler Journal: J Clin Oncol Date: 2018-06-06 Impact factor: 44.544
Authors: Jeffrey P Gross; Stephanie Powell; Frank Zelko; William Hartsell; Stewart Goldman; Jason Fangusaro; Rishi R Lulla; Natasha Pillay Smiley; John Han-Chih Chang; Vinai Gondi Journal: Neuro Oncol Date: 2019-07-11 Impact factor: 12.300
Authors: Derek S Tsang; Laurence Kim; Zhihui Amy Liu; Laura Janzen; Mohammad Khandwala; Eric Bouffet; Normand Laperriere; Hitesh Dama; Dana Keilty; Tim Craig; Vijay Ramaswamy; David C Hodgson; Donald Mabbott Journal: Neuro Oncol Date: 2021-03-25 Impact factor: 12.300
Authors: Ade Oyefiade; Iris Paltin; Cinzia R De Luca; Kristina K Hardy; David R Grosshans; Murali Chintagumpala; Donald J Mabbott; Lisa S Kahalley Journal: J Clin Oncol Date: 2021-04-22 Impact factor: 50.717